Facebook
Twitter
LinkedIn
Forward10th Symposium on Hemostasis: Coagulation, Platelets, and Transfusion Medicine - 2022
The bi-annual Symposium on Hemostasis is a multi-decade-long tradition that brings together both basic researchers and clinicians interested in studying the role of platelets, tissue factor, and coagulation proteases in hemostasis and thrombosis. This meeting has been a platform for communicating the most current information on the forefront of coagulation research, exchanging innovative ideas and establishing fruitful collaborations. Invited speakers and chairs of the sessions are well known leaders in the field of hemostasis and thrombosis research. The audience is composed of both researchers and hematology physicians. Prior symposia have provided a venue for premiere scientific communications, including presentations on tissue factor regulation by encryption phenomena, the mechanism of action of bypassing agents in hemophilia, novel animal models of hemophilia and traumatic bleeding, and in vivo wound healing models in hemophilia. The symposium planned for 2022 will continue to focus on the latest findings in the field of hemostasis and thrombosis. The meeting consists of several sessions focusing on: new insights into the basic biochemistry of coagulation; platelet production, function, and storage; mechanisms underlying thrombosis; and novel animal models to study bleeding and thrombosis. Important new research on the state of gene therapy for hemophilia and novel agents to treat hemophilia will also be presented. In addition, we will feature a new session to highlight the research of trainees attending the symposium.
Target Audience
Physicians, Fellows, Residents, and Medical Students
Learning Objectives
• Evaluate novel agents or mechanisms for hemophilia treatment. Recent studies on hemophilia treatment have gone beyond replacement therapy to consider gene therapy; blocking inhibitors of coagulation; and bifunctional antibodies as replacement therapy. Other studies have suggested that localization of coagulation factors outside of the vasculature can contribute to hemostasis, and studies on inhibition of the factor IXa/VIIIa complex have suggested targets for therapy. This symposium will provide new information on these therapeutic modalities.
• Evaluate how understanding basic mechanisms of thrombosis can lead to novel therapeutics. As we gain a better understanding of the basic mechanisms that drive thrombosis, we gain new targets for antithrombotic treatment. These basic mechanisms include an understanding of inflammatory pathways and which contact factors (XI, XII, high molecular weight kininogen) are triggered by these pathways. Animal models are especially important in understanding the complexities of thrombosis in vivo. This symposium will provide the basic knowledge to evaluate new therapeutics.
• Evaluate how to optimally use platelets for transfusion given that platelet storage can alter platelet function. Platelets are required for hemostasis. Disease or injury that reduce platelet number or function can currently only be treated by transfusion of stored platelets. The need for these transfusions is especially great in trauma. But storage of platelets alters their function. Upon completion of this learning activity, participants will be able to identify patients, especially trauma patients, for whom the appropriate therapy is platelet transfusion.
• Discuss the evolving knowledge on the interactions of inflammation with megakaryocytes and platelets. Recent studies have made clear that megakaryocytes and platelets are significant factors in the inflammatory response. While normally adaptive, this interaction can result in thrombosis in some settings. This symposium will provide information that may help drive appropriate use of platelet transfusions as well as anti-inflammatory agents.
AMA PRA Category 1 Credit
Available Credit
- 10.25 AMA PRA Category 1 Credit(s)™
- 10.25 Attendance